Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Jun 24, 2022 10:24am
390 Views
Post# 34780052

RE:RE:RE:RE:RE:It' could be that they are waiting for---

RE:RE:RE:RE:RE:It' could be that they are waiting for---Eoganacht ... I agree.

I'm pretty sure that TLT management will indeed produce a clearer picture @270 days, considering this recent statement:

As of May 30:

The maintenance study treatment (so, the 2nd dose) has been provided to 15 patients, with 11 maintenance study treatments pending


That should then set the tone for them to start promoting the technology to analysts and start getting coverages.  

We will have data to compare against competition on a more solid ground.  The underdosing of the first 12 patients prevented them to be proactive.  Now, with 11 pending results for the 270-day period, this could be more significant on the CR %.

Interesting time ahead, no doubt.

_____________________________

RE:RE:RE:RE:It' could be that they are waiting for---
We should have had 180 day results for the first 25 in March, 270 day results this month and 360 day results in September. It would be great if they let us know the 270 day CR rates of the first 25, which they should already have or will have shortly.
<< Previous
Bullboard Posts
Next >>